Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Saw Palmetto and Increased Clinical Response

Safety in these studies

Overall tolerabilityNo significant difference
No significant difference between SR and placebo (MD -1.22 cc, 95% CI -3.91 to 1.47) for prostate size; harms outcome not specifically quantified.
from: Serenoa repens for benign prostatic hyperplasia.
adverse events (general)Reported
The main outcome measure for harms was the number of men reporting side effects.
from: Serenoa repens for benign prostatic hyperplasia.

1 of 1 paper

Serenoa repens for benign prostatic hyperplasia.
- 2012-12-12
- Meta-Analysis · n = 5,666
- The Cochrane database of systematic reviews 12
- - James Tacklind
  - Roderick Macdonald
  - Indy Rutks
  - Judith U Stanke
  - Timothy J Wilt
- PubMed: 23235581
- DOI: 10.1002/14651858.cd001423.pub3
5 Insights on
- Increased Clinical Response
- High evidence
- Clinical
the proportions of clinical responders (≥ three-point improvement) were nearly identical (42.6% and 44.2% for SR and placebo, respectively), and not significant (RR 0.96, 95% CI 0.76 to 1.22).
Effect
Neutral
Effect size
Small
Significant
No
Dose
double and triple doses